The Quick Version
- Australian businesses spent $24.4 billion on R&D in 2023–24, yet R&D commercialisation in Australia remains a persistent challenge, with the country ranking 30th globally for innovation outputs despite ranking 18th for inputs
- The gap between R&D spending and the R&DTI refund can stretch past 12 months, creating real cash flow pressure during the most capital-intensive phase of commercialisation
- Funding options like equity, grants, and traditional debt all carry trade-offs. R&D finance offers a non-dilutive alternative by lending against the eligible R&D expenditure that a business has already incurred
- A structured commercialisation roadmap, aligned with the right funding at each stage, helps businesses move from research to revenue without stalling
- R&D finance complements the R&DTI. It doesn’t replace it, and Rocking Horse doesn’t assess R&DTI eligibility or assist with the application
Ask a growth-stage CFO about R&D commercialisation in Australia, and you’ll hear a familiar frustration. The company is spending more on research and development than ever. The technology works. But somehow, the revenue hasn’t caught up.
They’re not alone. In 2023–24, Australian businesses collectively invested $24.4 billion in R&D, an 18% jump from two years earlier. Yet the gap between that investment and the commercial returns it produces keeps widening. Capital runs short between milestones. Government incentives designed to support innovation last long after the money has been spent. And each quarter, the board asks the same question: where’s the return?
This guide breaks down what R&D commercialisation in Australia actually involves, where the system supports businesses and where it falls short, and how growth-stage companies can close the gap between research investment and commercial results.
What Does It Mean to Commercialise R&D?
Commercialising R&D means converting research into a marketable product or service that generates revenue. Not just a working prototype. Not just a successful trial. A commercial outcome with paying customers.
In practice, the process spans everything from protecting intellectual property and validating demand through to acquiring customers and scaling operations. For a SaaS company, it might look like transitioning from beta to paid subscriptions. For a biotech firm, it could mean moving from trial results to regulatory clearance and first sales. The industry varies; the challenge doesn’t. Commercialisation is expensive, and it occupies a funding gap between the R&D budget and the sales budget that neither was built to cover.
The R&D Commercialisation Gap in Australia
The Australian Government’s landmark review of the nation’s R&D system, the Ambitious Australia report (published in December 2025), identified this as a system-level failure. It found that Australia has ‘too much focus on inputs and too little on turning ideas and knowledge into products, products into growth, and growth into jobs.’ Translating knowledge into new products and services that create economic impact, the report argues, is where Australia consistently falls short. Despite cataloguing more than 150 Commonwealth R&D programmes, the panel concluded that funding is spread too thinly to produce meaningful commercialisation outcomes.
The data tells the same story. According to DISR’s analysis of global innovation indicators, Australia ranks 18th globally for innovation inputs (institutions, human capital, and infrastructure) but drops to 30th for innovation outputs in the Global Innovation Index. And while 45.7% of Australian businesses reported engaging in innovation activity in 2022–23, a striking 94.8% of those innovations were existing products or processes adopted from elsewhere. Only a fraction were genuinely new to the world.
When it comes to R&D commercialisation, Australia has a translation problem. Businesses are doing the research. The commercial returns aren’t following at anywhere near the same pace.
The Australian R&D Investment Picture: Opportunity and Challenge
On paper, Australia’s R&D investment looks healthy. The latest ABS data shows business R&D spending reached $24.4 billion in 2023–24. The professional, scientific, and technical services sector led with $9.2 billion (a 31.5% increase from the prior period), and human resources devoted to R&D hit 104,172 person-years of effort.
Dig beneath the headline, though, and cracks appear. BERD as a proportion of GDP has sat at 0.9% since 2017–18. The dollar figure is growing, but it hasn’t outpaced the broader economy. Australia’s total R&D intensity sits at approximately 1.69% of GDP, compared with an OECD average of 2.72%. South Korea and Germany are above 3%. The Australian Academy of Science has estimated that business sector underinvestment alone has left a gap of $32.5 billion simply to reach the OECD average.
Government Support: Significant, but With a Catch
The R&D Tax Incentive is the centrepiece of Australia’s government support for business R&D. It provides a tax offset for companies investing $20,000 or more in eligible research and development. For companies with aggregated turnover under $20 million, the refundable offset rate currently sits at the company tax rate plus 18.5 percentage points, effectively 43.5% for most eligible entities.
The ATO’s second R&D Tax Incentive Transparency Report (covering 2022–23) showed 12,956 companies invested $16.2 billion in R&D through the programme. It’s a substantial incentive. But it wasn’t designed to solve cash flow timing, and that matters enormously when you’re trying to commercialise.
The barriers that hold R&D commercialisation in Australia back aren’t about ambition or capability. They’re structural: incentive payments that arrive long after the critical window has passed, a web of programmes that takes real effort for growth-stage companies to work through, and an intensity gap that limits the pipeline of commercially viable research. So what does that mean for businesses on the ground?
The Cash Flow Problem at the Heart of R&D
Here’s the timing problem nobody warns you about. R&D expenditure is continuous. Salaries, contractor invoices, cloud infrastructure, testing equipment, and materials don’t pause for the end of the financial year. But the R&DTI refund arrives as a single lump sum from the ATO, well after year-end, once registration with DISR is complete and the company tax return has been processed. For companies with a standard 30 June year-end, the gap between spending on eligible R&D and receiving the corresponding refund can stretch past 12 months.
That creates an operational problem with real teeth. The capital needed to hire a go-to-market team, fund a product launch, or ramp up production is locked inside a refund that hasn’t landed yet. And every month of waiting compounds the cost.
What Delayed Capital Actually Costs
A product launch that slips by six months doesn’t just cost the development budget. It costs the revenue that the launch would have generated, the market position the company would have held, and the momentum behind a hiring plan that’s now stalled. The Productivity Commission’s 2026 Annual Productivity Bulletin recorded multifactor productivity declining by 0.5% in 2024–25, falling below the 20-year average and continuing a pattern of weak performance that stretches back more than a decade. Delayed commercialisation at the firm level feeds directly into that national trend.
For growth-stage businesses running tight budgets, the lag between R&D expenditure and the R&DTI refund forces difficult choices: defer hiring, pause go-to-market activity, or raise equity that wasn’t part of the plan. Each option costs you something. And in competitive markets, the company that moves first usually wins, regardless of whose technology was better.
DISR’s own research supports the connection between R&D activity and productivity outcomes, noting that ‘businesses conducting R&D are more productive and better at adopting existing innovations’. R&D pays off. The question is whether your business can afford to stay the course long enough to realise the return.
Funding Strategies to Accelerate Commercialisation
Capital doesn’t wait for tax refunds. When commercialisation demands funding that hasn’t arrived yet, businesses typically weigh four main options: equity funding, government grants, traditional debt, and R&D finance. Each plays a role. Each involves trade-offs that matter.
Equity provides capital without repayment obligations, but it dilutes ownership. If you’ve already raised seed or Series A funding, further dilution reduces your control and affects the economics of future rounds. Fundraising cycles also take time, often six months or longer. That rarely suits a commercialisation timeline that needs to move now.
Government grants are non-dilutive and don’t require repayment, making them attractive on paper. But they’re competitive, programme-specific, and increasingly limited. The Accelerating Commercialisation programme, once a key federal pathway, closed to new applications in May 2023. The Industry Growth Program is in wind-down. You can’t build a commercialisation plan around funding that might not be there when you need it.
Traditional debt offers speed without equity dilution, but it typically requires collateral, personal guarantees, and regular repayments. If you’re pre-revenue and R&D-heavy, that’s a difficult combination. For a fuller comparison of how these structures stack up, Rocking Horse’s guide to debt financing vs. equity financing is worth reading.
Where R&D Finance Fits
R&D finance fills a specific gap that the other options don’t easily address. It provides capital against your company’s year-to-date eligible R&D expenditure: spending that’s already happened, confirmed by your R&D tax consultant through a comfort letter. Because the loan is secured against expenditure you’ve already incurred (not projections or forecasts), it gives you earlier access to capital you’ve effectively earned through the R&DTI, without waiting months for the refund to arrive.
The structure is non-dilutive. No equity, no personal guarantees, and no restrictions on how the funds are used, whether that’s further R&D, hiring, a product launch, or operational costs during commercialisation. The loan settles automatically when the ATO processes your R&DTI refund.
For growing businesses managing significant R&D spend across a financial year, multiple drawdowns are available as eligible expenditure accrues. That means you can align funding to your commercialisation timeline rather than the tax calendar. And if you don’t yet have an R&D tax advisor, Rocking Horse can connect you with a trusted one from their network. Eligibility for the R&DTI itself is assessed by the advisor, not the lender. Rocking Horse’s role is purely financial.
How to Build a Commercialisation Roadmap
Strong research and adequate funding aren’t enough on their own. What separates businesses that turn R&D into revenue from those that stall is a structured plan for getting from development to market, with the right capital aligned to each stage. Here’s what that looks like in practice.
Protect What You’ve Built
Before your product reaches the market, the intellectual property behind it needs to be locked down. Patents, trademarks, design registrations, and trade secrets protect the competitive advantage your research has created. IP protection isn’t just a legal formality. It’s a prerequisite for investor confidence, a critical asset in licensing or partnership negotiations, and often the first thing a prospective acquirer will assess.
This stage is relatively low-cost compared to what follows, but it’s time-sensitive. If you’re spending on patent attorneys and IP strategy while waiting for an R&DTI refund that’s still months away, that cost compounds. Getting your IP house in order early, funded properly, avoids scrambling later when the stakes are higher.
Validate the Market
Market validation is where you move from ‘technically works’ to ‘customers will pay for it.’ This is where the business model gets pressure-tested: pricing, unit economics, distribution channels, and willingness to pay. Targeted market research, early adopter feedback, and pilot programmes all play a role.
R&D-intensive companies sometimes resist this stage, preferring to keep refining the technology. That instinct is expensive. Every month spent perfecting a product or service nobody has agreed to buy is a month of burn rate without revenue progress. The sooner you test against real demand, the sooner the path to revenue becomes clear, and the sooner you can redirect spend where it actually matters.
Plan and Execute Go-to-Market
This is where the cash flow pressure peaks. A go-to-market plan covers distribution channels, sales hires, customer acquisition, marketing spend, and the operational infrastructure needed to deliver at scale. For most R&D-intensive companies, go-to-market is the single most capital-intensive phase of commercialisation.
If your R&DTI refund is 12 months away and your product is ready to launch now, the mismatch is stark. This is exactly the stage where R&D financing can have the biggest impact: bridging the gap between the eligible spend you’ve already incurred and the refund you’re waiting on, so your launch timeline is set by the market opportunity rather than the tax calendar.
Scale With Discipline
Scaling too early burns cash. Scaling too late lets competitors establish positions you’ll struggle to reclaim. The key is matching production capacity, team growth, and market expansion to validated demand rather than projections.
If you’re planning to scale in the second half of the financial year, map your funding sources against the timeline. When does your R&DTI refund arrive? Can you draw down against accrued R&D spend in the interim? What’s the gap between your current cash position and the capital required to hit your next milestone? These are the questions that separate disciplined scaling from wishful thinking.
For businesses focused on R&D commercialisation, Australia’s incentive structure is genuinely supportive. But only if the timing is managed proactively. A roadmap that accounts for when capital will be needed, not just how much, makes the difference between a plan that works on paper and one that survives contact with reality.
Making the R&DTI Work Harder for Your Business
The R&DTI does exactly what it was designed to do: reduce the after-tax cost of research and development. For companies with turnover under $20 million, the R&D Tax Incentive delivers a refundable offset that can meaningfully improve the economics of innovation. The problem is what it wasn’t designed to do.
The timing constraint is real. The R&DTI was designed to lower the after-tax cost of innovation across a financial year cycle. It was never intended to provide working capital during the months when that innovation is being commercialised. If you’re spending heavily on R&D in the first half of the year, the refund for that activity may not arrive for 12–18 months. Twelve months is a long time to wait when your competitors aren’t waiting.
R&D finance addresses that specific timing mismatch. By borrowing against eligible R&D expenditure you’ve already incurred, confirmed via a comfort letter from your R&D tax consultant, you can access funds tied to your R&DTI entitlement before the ATO processes the refund. The two work in parallel: the R&DTI determines the value of the incentive, and R&D finance provides earlier access to the capital it represents.
To be clear about what this doesn’t involve: Rocking Horse does not replace the R&DTI, does not assess eligibility for the incentive, and does not assist with the R&DTI application or registration. Those responsibilities sit with you and your R&D tax advisor. Rocking Horse is a lender. They provide R&D financing secured against confirmed eligible expenditure.
The 2026–27 Federal Budget announced proposed reforms to the R&DTI, with changes expected to take effect from 1 July 2028 (subject to legislation). These include higher offset rates for core R&D expenditure, a lift in the refundable offset turnover threshold from $20 million to $50 million, and the removal of supporting R&D expenditure eligibility. The Budget estimates these changes will drive $400 million per year in additional R&D by young firms. For businesses planning their R&D strategy over the coming years, staying across these proposed changes is important, but they don’t alter the fundamental timing problem that R&D finance is designed to address.
What Australian Businesses Are Getting Right
The R&D commercialisation Australia needs won’t come from more research funding alone. It requires better timing, sharper planning, and capital that arrives when the opportunity does. The companies that successfully turn R&D into revenue understand this. They treat commercialisation as a distinct strategic phase with its own budget, timeline, and milestones, not as an afterthought attached to the end of a research project. They plan their funding before cash runs short. And they use every incentive available, including the R&DTI, without letting its timing dictate their pace.
DISR data shows that R&D-active businesses consistently outperform their non-R&D peers on productivity and commercial outcomes. The evidence is clear: companies that invest in R&D and manage the commercialisation process deliberately are better positioned to grow.
Consider a growth-stage SaaS company spending $1.5 million on eligible R&D across the financial year. Rather than waiting 12+ months for the R&DTI refund, the company draws down against its accrued R&D spend each quarter. That capital funds three senior hires in product and sales six months before the refund lands. By the time the ATO processes the rebate and the loan settles, the revenue those hires generated has already exceeded the cost of the facility. The company didn’t give up equity, didn’t stall its launch, and didn’t restructure its roadmap around the tax calendar. It moved when the market was ready.
Closing the Gap Between Research and Revenue
The pattern behind successful R&D commercialisation in Australia isn’t a single strategy or funding source. It’s the combination of strong research, a structured plan, and financial flexibility — the ability to act on commercial opportunities when they arise, not when the tax calendar allows.
That’s the kind of outcome Rocking Horse Group was built to support. We’re a specialist R&D finance lender, and we work with startups, scaleups, and established businesses across Australia to bridge the timing gap between R&D expenditure and the R&DTI refund. We don’t assess R&DTI eligibility, lodge claims, or provide tax advice. We lend against eligible R&D spend that’s already been incurred and confirmed by your R&D tax consultant, so your cash flow keeps pace with your commercialisation timeline.
The BCA and Mandala Partners estimated in July 2025 that better commercialisation incentives could generate $7.7 billion in annual economic output and drive an additional $2 billion in annual business R&D spending. That opportunity starts with individual businesses making smarter decisions about how and when they fund the journey from research to revenue.
Not sure how much your company could access? Talk to our team about your situation, or try the R&D expenditure calculator to get an estimate.
Frequently asked questions
What does R&D commercialisation mean for Australian businesses?
R&D commercialisation is the process of turning research and development outcomes into products, processes, or services that generate revenue. For Australian businesses, it involves moving from the development phase through IP protection, market validation, and go-to-market execution. It’s where R&D investment starts producing a financial return, and it’s often the most underfunded and poorly planned stage of the innovation cycle.
How long does the R&DTI refund take to arrive?
The R&DTI refund is paid as a lump sum after the end of the income year, once R&D activities have been registered with DISR and the company tax return has been processed by the ATO. For companies with a standard 30 June year-end, this process can take 12 months or longer from the point where the R&D expenditure was incurred. That timing gap is one of the key cash flow challenges for businesses in the commercialisation phase.
Can I access R&D finance before my R&DTI claim is lodged?
Yes. R&D finance is based on the year-to-date eligible R&D expenditure your company has already incurred, confirmed by a comfort letter from your R&D tax consultant. You don’t need to have lodged or completed your R&DTI claim to access funding. The loan is repaid automatically when the ATO processes the refund.
Does R&D finance replace the R&D Tax Incentive?
No. R&D finance and the R&DTI are interconnected, not competing. A company must be eligible for the R&DTI (or planning to claim it) to access R&D finance. The R&DTI determines the value of the government incentive. R&D finance simply provides earlier access to the capital that incentives represent, through a loan secured against eligible expenditure. Rocking Horse does not assess R&DTI eligibility, lodge claims, or provide tax advice.
What can I spend R&D finance on?
There are no restrictions on how R&D finance funds are used. Businesses can put the capital toward further R&D, hiring, product launches, go-to-market activity, operational costs, or any other purpose. The loan is secured against eligible R&D expenditure already incurred, not against the use of the funds themselves.